The JVCKENWOOD Group develops products for the healthcare industry by making use of the unique expertise that we possess in image and video processing technologies and in optical disk technologies. Seeking to ensure that as many people as possible receive appropriate medical services, we assist those working at the frontlines of medicine by developing medical image display monitors with high diagnostic interpretation efficiency as well as a particle (exosome) measuring instrument that is expected to enable extremely early diagnosis. The healthcare business is also a field that will have a strong impact on the super-aging society, and, as such, we are striving to develop and launch products that meet the needs of medical professionals.
Market launch of high-resolution medical image display monitor
In 2017, we launched the MS55i2plus and i3 Series (CL-S200/CL-S300) as new major products in the medical image display monitor market.
The MS55i2plus, a mammography and tomosynthesis image display monitor, achieves higher luminance and contrasts compared to traditional medical monitors. As such, it improves visibility of micro calcifications, tumors and structures. Furthermore, with regard to images of high-density mammary glands containing lesions, the increased sense of depth that is achieved will likely help improve radiogram interpretation efficiency.
The i3 Series are medical image display monitors that achieve both the accurate reproduction of monochrome images and a combined diagnosis (multimodality) interpretation environment that makes use of various images in color, including those from ultrasound, endoscope, and pathology tests. In particular, our unique Dynamic Gamma* function automatically distinguishes between monochrome and color images that are intermixed on the screen, in units of pixels. Thus, each image is displayed in the optimal tonal scale in real time. This contributes to improving efficiency in the radiogram interpretation process by enhancing the readability of color images.
* Patent No. 6277984
In fiscal 2018, we have actively promoted to launch these medical image display monitors onto the market. In fiscal 2020, we will enhance the lineup with further advanced i3 Series monitors and strive to provide optimal radiogram interpretation environments for everyone involved in interpreting radiograms.
Please see the links provided below for further details.
- Medical image display monitor: MS55i2plus
- Medical image display monitor: i3 Series (CL-S200)
- Medical image display monitor: i3 Series (CL-S300)
Development of ExoCounter that supports very early diagnosis of diseases
As the world braces for the challenges of an aging society and the increased burden of medical costs, increasing importance is placed on pre-disease diagnosis stemming from the advancement in preventative medicine, and even more on very early diagnosis performed during the disease-free period through exams conducted at the cell and particle level. The exosome is a vesicle particle measuring approximately 50–100 nm in diameter that is released from a variety of types of cells, and exists in body fluids such as blood, saliva, and urine. Exosomes are embedded with various substances including protein, mRNA*1, and micro RNA*2, and as of recent years these substances are expected to serve as biomarkers for various diseases including cancer. We combined our properties in optical disk and nanobead technologies to develop an exosome measurement system called ExoCounter that detects and measures each antigen-specific exosome in body fluids.
In March 2016, we started working with Sysmex Corporation for the joint development of diagnostic equipment dealing with exosomes. For the future, we aim to proceed with clinical tests with the goal of putting the equipment to use to enable the early discovery of cancer through the use of blood, since blood tests pose a low physical burden on examinees. In October 2017, we began collaborative research with the National Cancer Center Japan, Sysmex Corporation, and Daiichi Sankyo Co., Ltd. with the aim of raising the quality of cancer diagnosis and treatment. In this collaborative project, our company is developing the technology to detect exosomes related to the illness.
Furthermore, our joint research conducted together with the Keio University School of Medicine and the Tokyo Medical University discovered for the first time that breast cancer and ovarian cancer patients have a statistically and significantly high number of cancer-specific exosomes in their serum (please see the press release issued August 9, 2018). The results of this research are expected to help further advance the development of new cancer diagnosis and treatment methods using exosomes, and help advance studies on cancer.
Based on the results of the above research, JVCKENWOOD will continue to work toward answering the needs of society by providing products that will realize very early diagnosis of illnesses and enable treatment that is suitable for each individual patient.
- *1 mRNA
- mRNA (messenger RNA) is RNA that copies and conveys genetic information on protein synthesis from the DNA sequence.
- *2 microRNA
- microRNA (miRNA) is one chain of an RNA molecule about the length of 20 nucleotides, and is associated with performing the role of controlling the expression of numerous genes and proteins. In recent years, miRNA found in exosomes has been attracting attention as being effective in the diagnosis of diseases because it remains stable and will not be degraded by enzymes in the blood, and because it changes dramatically in terms of amount and type depending on the type of disease and its level of development.
- *3 Nanobead
- Nanobeads are beads measured on the scale of nanometers (nm, one-millionth of a millimeter). The nanobeads used in this technology have a diameter of about 200 nm. The surface of the beads is solid-phased with an antibody that docks with substances on the exosomes, which enables the detection of specific exosomes that are being looked for.
Please see the link provided below for further details.